Cargando…
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
BACKGROUND: Severe eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation. Post-hoc analyses from a pivotal clinical trial have demonstrated the enhanced efficacy of benralizumab on asthma ou...
Autores principales: | D'Amato, Maria, Menzella, Francesco, Altieri, Elena, Bargagli, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Ori, Alessandra, Simoni, Lucia, Boarino, Silvia, Vitiello, Gianfranco, Aliani, Maria, Del Giacco, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234857/ https://www.ncbi.nlm.nih.gov/pubmed/35769575 http://dx.doi.org/10.3389/falgy.2022.881218 |
Ejemplares similares
-
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study
por: Menzella, Francesco, et al.
Publicado: (2022) -
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
por: Caruso, Cristiano, et al.
Publicado: (2022) -
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
por: Vultaggio, Alessandra, et al.
Publicado: (2023) -
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm(3): A Post Hoc Analysis from the ANANKE Study
por: Senna, Gianenrico, et al.
Publicado: (2022) -
Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)